NCT03059797 - Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

May 6, 2019

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Anlotinib

Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

DRUG

Placebo

Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

Trial Locations (12)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

The 307th Hospital of Chinese People's Liberation Army, Beijing

Liaoning Cancer Hospital, Shenyang

Jilin Cancer Hospital, Changchun

Harbin medical university affiliated tumor hospital, Harbin

Shanghai Chest Hospital, Shanghai

Linyi Cancer Hospital, Linyi

Tianjin Medical University Cancer Hospital, Tianjin

Hunan Cancer Hospital, Changsha

Henan Cancer Hospital, Zhengzhou

Guangdong General Hospital, Guangzhou

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou